IP Library Granted Patent US 11,241,271
Granted Patent B2
US 11,241,271 · App. 16/514,316 · Granted Feb 8, 2022

Methods of treating nasal airways

Inventors: Scott J. Wolf (Menlo Park, CA); Andrew Frazier (Sunnyvale, CA)
Assignee: Aerin Medical Inc.
A61B18/14A61B18/02A61B18/1206A61B18/1485A61N1/403A61B5/01A61B17/2816A61B17/320068A61B18/06A61B18/085A61B18/12A61B18/1442A61B18/1445A61B18/1477A61B18/16A61B18/18A61B18/1815A61B18/20A61B2017/248A61B2017/32007A61B2017/320069A61B2018/00005A61B2018/0016A61B2018/0022A61B2018/00023A61B2018/0091A61B2018/00178A61B2018/00327A61B2018/00577A61B2018/00595A61B2018/00642A61B2018/00702A61B2018/00708A61B2018/00791A61B2018/00821A61B2018/00875A61B2018/00886A61B2018/00922A61B2018/00982A61B2018/00994A61B2018/0212A61B2018/0225A61B2018/0262A61B2018/126A61B2018/1253A61B2018/143A61B2018/1425A61B2018/1807A61B2018/1861A61F5/08A61F5/56A61F7/10A61N5/025A61N5/0603A61N5/0625A61N7/022F04C2270/041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,271
App. No.
16/514,316
Granted
Feb 8, 2022
Kind
B2
Abstract

A device is described for treating a nasal airway by modifying a property of a nasal tissue of or near a nasal valve of the airway, without using a surgical incision or an implant, to decrease airflow resistance or perceived airflow resistance in the nasal airway. Various embodiments include an elongate shaft, a bipolar radiofrequency delivery member extending from one end of the shaft, and a handle attached to the elongate shaft at an opposite end from the radiofrequency delivery member. The radiofrequency delivery member is sized to be inserted into a nose and configured to at least temporarily deform the nasal tissue and deliver radiofrequency energy. The radiofrequency delivery member includes two rows of protruding electrodes disposed on a tissue contact surface, and the device is configured to deliver radiofrequency energy from one row of electrodes to the other row of electrodes.

Claims (25)

1. A method for treating a nasal airway to reduce mucus production, the method comprising:

contacting a treatment element of a nasal airway treatment device directly with nasal mucosa of the nasal airway, wherein the treatment element comprises two rows of bipolar electrode pairs;

applying radiofrequency energy with the bipolar electrode pairs through the nasal mucosa to a target tissue underlying the nasal mucosa for an amount of time to heat the target tissue; and

removing the treatment element from the nasal airway,

wherein heating the target tissue with the applied radiofrequency energy modifies at least one property of the target tissue, and

wherein the modified at least one property of the target tissue causes a reduction in mucus production in the nasal airway.

2. The method of claim 1 , wherein the target tissue is selected from the group consisting of mucosa, submucosa, cartilage, muscle, ligament, and tendon.

3. The method of claim 1 , further comprising controlling at least one characteristic of the applied radiofrequency energy with a control system coupled with the nasal airway treatment device.

4. The method of claim 1 , wherein the radiofrequency energy is applied in the form of a 460 kHz sinusoid wave.

5. The method of claim 1 , further comprising:

sensing a temperature of the nasal mucosa using a thermocouple positioned between the two rows of bipolar electrode pairs on the treatment element; and

modifying an amount of the radiofrequency energy applied to the target tissue based on the sensed temperature.

6. The method of claim 1 , further comprising displaying one or more parameters of treatment on a console attached to the nasal airway treatment device while the radiofrequency energy is applied, the one or more parameters selected from the group consisting of treatment time, power level, temperature sensed by the treatment element, electric impedance, electric current, and depth of treatment.

7. The method of claim 1 , further comprising applying local anesthesia to at least one of the nasal mucosa or the target tissue before applying the radiofrequency energy.

8. The method of claim 1 , wherein the radiofrequency energy is produced by a radiofrequency energy source configured to run between 1 Watt and 100 Watts.

9. The method of claim 1 , wherein applying the radiofrequency energy comprises heating the target tissue to a temperature between 50 degrees Celsius to 70 degrees Celsius.

10. The method of claim 1 , wherein the amount of time the radiofrequency energy is applied to the target tissue is between fifteen seconds and one minute.

11. The method of claim 1 , further comprising, before removing the treatment element from the nasal airway:

repositioning the treatment element to contact a different portion of nasal mucosa; and

applying radiofrequency energy with the bipolar electrode pairs through the different portion of nasal mucosa to a different portion of target tissue for the amount of time to heat the different portion of target tissue.

12. The method of claim 1 , wherein the modified at least one property of the target tissue is selected from the group consisting of shrinking, tightening, stiffening, and deactivating the target tissue.

13. The method of claim 1 , further comprising repositioning, remodeling, or reshaping the target tissue with the treatment element, wherein the target tissue remains at least partially repositioned, remodeled or reshaped after the target tissue heals.

14. The method of claim 1 , wherein applying the radiofrequency energy heats the target tissue to a sub-ablative temperature.

15. The method of claim 1 , further comprising applying a conductivity enhancing substance to the nasal mucosa before contacting the treatment element with the nasal mucosa.

16. The method of claim 1 , further comprising bending a shaft of the nasal airway treatment device before contacting the treatment element with the nasal mucosa.

Assignments (2)
SECURITY INTEREST Recorded Dec 20, 2024
From: AERIN MEDICAL INC.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 069746/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2019
From: WOLF, SCOTT J.; FRAZIER, ANDREW
To: AERIN MEDICAL, INC.
Reel/Frame 049779/0307 →
Continuity (10)
Continuation 15596455 · May 16, 2017
Continuation 15248935 · Aug 26, 2016
Continuation 14864428 · Sep 24, 2015
Continuation 14737196 · Jun 11, 2015
Continuation 14607639 · Jan 28, 2015
Continuation 14026922 · Sep 13, 2013
Continuation In Part 13495844 · Jun 13, 2012
Provisional Application 61603864 · Feb 27, 2012
Provisional Application 61496930 · Jun 14, 2011
Related Publication 20190336196A1 · Nov 7, 2019
Cited By (22)
US 12,245,803 US 12,268,433 US 12,279,808 US 12,336,750 US 12,357,378 US 12,357,817 US 12,364,532 US 12,369,963 US 12,369,966 US 12,369,973 US 12,446,953 US 12,471,978 US 12,484,946 US 12,484,957 US 12,527,618 US 12,558,536 US 12,564,521 US 12,616,514 US 12,636,058 US 12,636,073 US 12,678,212 US 12,690,907